t(7;12)(q36;p13) and t(7;12)(q32;p13)--translocations involving ETV6 in children 18 months of age or younger with myeloid disorders.
Our retrospective karyotype review revealed two rare recurrent translocations affecting ETV6 (TEL): t(7;12)(q36;p13) and t(7;12)(q32;p13). Five patients with a t(7;12) were from a group of 125 successfully karyotyped pediatric patients enrolled in consecutive clinical AML trials of the Dutch Childhood Leukemia Study Group over a period of 7 years. During a search of available cytogenetic databases, we found 7q and 12p abnormalities in two additional Dutch patients and in three participants in Pediatric Oncology Group trials. A del(12p) had been initially identified in four of these patients and re-examination of the original karyograms revealed a t(7;12)(q36;p13) in two instances and a probable t(7;12) in the other two. FISH confirmed the presence of a t(7;12)(q36;p13) in the latter. Most (n = 7) also had trisomy 19. The t(7;12)(q36;p13) (n = 9) was more common than the t(7;12)(q32;p13) (n = 1). These subtle translocations were found only in children 18 months of age or younger. A literature search revealed that the t(7;12) with break-points at 7q31-q36 and 12p12-p13 had been reported in six children with myeloid disorders and in two with acute lymphoblastic leukemia; all were 12 months of age or younger. Only two of the 17 for whom survival data were available, were alive after at least 22 months of continuous complete remission. Our findings suggest that ETV6 rearrangements due to a t(7;12) may play an adverse role in myeloid disorders in children 18 months of age or younger. Therefore, children in this age group with myeloid disorders should be screened for both MLL and ETV6 rearrangements.
Slater
R M
RM
Department of Clinical Genetics, Erasmus University, Rotterdam, The Netherlands.
von Drunen
E
E
Kroes
W G
WG
Weghuis
D O
DO
van den Berg
E
E
Smit
E M
EM
van der Does-van den Berg
A
A
van Wering
E
E
Hählen
K
K
Carroll
A J
AJ
Raimondi
S C
SC
Beverloo
H B
HB
D000208:Acute Disease; D000754:Anemia, Refractory, with Excess of Blasts / Q000235:genetics; D019457:Chromosome Breakage; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics* / Q000648:ultrastructure; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics* / Q000648:ultrastructure; D004268:DNA-Binding Proteins / Q000235:genetics*; D016208:Databases, Factual; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D007438:Introns / Q000235:genetics; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000235:genetics*; D008297:Male; D009426:Netherlands; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics; D050783:Proto-Oncogene Proteins c-ets; D012097:Repressor Proteins; D012189:Retrospective Studies; D017384:Sequence Deletion; D014157:Transcription Factors / Q000235:genetics*; D014178:Translocation, Genetic; D014314:Trisomy; D000097764:ETS Translocation Variant 6 Protein
D004268:DNA-Binding Proteins; D050783:Proto-Oncogene Proteins c-ets; D012097:Repressor Proteins; D014157:Transcription Factors; D000097764:ETS Translocation Variant 6 Protein